PAX1m/JAM3m Testing Offered Superior Triage Performance For Detecting CIN3+ In Women With hrHPV, Study Finds

Oncology Nurse Advisor (12/30, Garlapow) reports, “PAX1/JAM3 methylation (PAX1m/JAM3m) testing offered superior triage performance for detecting cervical intraepithelial neoplasia grade 3 or worse (CIN3+) in high-risk human papillomavirus (hrHPV)-positive women, according to” study results. Investigators found that “compared with liquid-based cytology...and HPV 16/18 genotyping, DNA methylation testing of PAX1 and JAM3 achieved the highest specificity, demonstrated a stronger predictive value, and substantially reduced unnecessary referrals to colposcopy.” The findings were published in The Oncologist.